APA

Resende C. B., Rezende B. M., Bernardes P. T. T., Teixeira G. M., Teixeira M. M., Pinho V. & Bittencourt H. (20171113). Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. : Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Chicago

Resende C B, Rezende B M, Bernardes P T T, Teixeira G M, Teixeira M M, Pinho V and Bittencourt H. 20171113. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. : Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Harvard

Resende C. B., Rezende B. M., Bernardes P. T. T., Teixeira G. M., Teixeira M. M., Pinho V. and Bittencourt H. (20171113). Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. : Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

MLA

Resende C B, Rezende B M, Bernardes P T T, Teixeira G M, Teixeira M M, Pinho V and Bittencourt H. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. : Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 20171113.